Thorgate
Start free trial
Trademark owner · USPTO register · rebuilt nightly

Celgene Corporation

183 live US trademarks, filing since 1997. The 26th largest trademark holder in Class 5 (pharmaceuticals). 39 new applications filed this year.

Get alerts when they file Check a name against the register
Live marks
183
registered + pending
Registered
78
on the Principal Register
Pending
105
10 open to opposition
Filed in 2026
39
15 intent to use
Classes used
10
of 45 Nice classes
First filing
1997
29 years on the register
At a glanceplain-language reads of the register
Mostly pharmaceuticals: 149 of 183 live marks are in Class 5. Medical & beauty services (Class 44) is next with 18.
Filing faster than usual: 39 applications so far in 2026 against a yearly average of 8.7.
New products ahead: 15 of the 39 filings this year are intent-to-use applications, meaning the goods are not yet on sale.
10 marks are open to opposition now; the windows close between Nov 5 and Nov 5.
8 registrations have a maintenance filing due in the next 12 months, 8 already in the grace period.
Filing activityapplications per year, by filing date
0 52 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 41 so far

Marks held on the register, by filing date. 2026 is year to date.

Portfolio by classlive marks · rank among filers in that class

A multi-class mark counts once per class. Rank shown where the owner is in the class's top 50.

Latest activity

What Celgene Corporation filed most recently.

MarkClassFiledBasisStatusSerial
ONXARVIQ 5 Jun 8, 2026 intent to use pending 99871321
ONZARVIQ 5 Jun 8, 2026 intent to use pending 99871326
ORDEGRIA 5 Jun 8, 2026 intent to use pending 99871329
REYXARGO 5 Jun 8, 2026 intent to use pending 99871333
TREVRAYO 5 Jun 8, 2026 intent to use pending 99871338
VOZDEGRA 5 Jun 8, 2026 intent to use pending 99871339
XEBRYAR 5 Jun 8, 2026 intent to use pending 99871344
DEYDESGO 5 Jun 8, 2026 intent to use pending 99872207
DEGARVI 5 Jun 8, 2026 intent to use pending 99872213
ARZODUA 5 Jun 8, 2026 intent to use pending 99872219
Open to opposition now30-day windows from publication
DEGZERV · Cl. 5 · published Oct 6
closes Nov 5
ARXELDU · Cl. 5 · published Oct 6
closes Nov 5
ONXELDAR · Cl. 5 · published Oct 6
closes Nov 5
ZEMDEZOS · Cl. 5 · published Oct 6
closes Nov 5
ARXELBRO · Cl. 5 · published Oct 6
closes Nov 5
ONXARLIS · Cl. 5 · published Oct 6
closes Nov 5
XEYDEGRO · Cl. 5 · published Oct 6
closes Nov 5
ARVREYZO · Cl. 5 · published Oct 6
closes Nov 5
DEZARQLI · Cl. 5 · published Oct 6
closes Nov 5
DEGLIBAR · Cl. 5 · published Oct 6
closes Nov 5

Anyone who believes they would be harmed by registration can oppose during this window.

Maintenance windows aheadnext 12 months · from registration dates
R² · Reg. 6,042,656 · registered Apr 2020
Section 8 declaration (years 5–6) · in grace period until Oct 28, 2026
Apr 28, 2025 → Apr 28, 2026
MS WS MULTIPLE SCLEROSIS WORK SPACE · Reg. 6,049,737 · registered May 2020
Section 8 declaration (years 5–6) · in grace period until Nov 5, 2026
May 5, 2025 → May 5, 2026
LELLOKEY · Reg. 6,046,318 · registered May 2020
Section 8 declaration (years 5–6) · in grace period until Nov 5, 2026
May 5, 2025 → May 5, 2026
ASTOTLEO · Reg. 6,046,320 · registered May 2020
Section 8 declaration (years 5–6) · in grace period until Nov 5, 2026
May 5, 2025 → May 5, 2026
ENHARNEX · Reg. 6,052,097 · registered May 2020
Section 8 declaration (years 5–6) · in grace period until Nov 12, 2026
May 12, 2025 → May 12, 2026
R2 REVLIMID/RITUXIMAB · Reg. 6,073,615 · registered Jun 2020
Section 8 declaration (years 5–6) · in grace period until Dec 9, 2026
Jun 9, 2025 → Jun 9, 2026
BOLDER SCIENCE · Reg. 6,091,947 · registered Jun 2020
Section 8 declaration (years 5–6) · in grace period until Dec 30, 2026
Jun 30, 2025 → Jun 30, 2026
BOLDER SCIENCE · Reg. 6,091,961 · registered Jun 2020
Section 8 declaration (years 5–6) · in grace period until Dec 30, 2026
Jun 30, 2025 → Jun 30, 2026

A filing missed by the due date enters a six-month grace period, then the registration cancels.

Other large filers in Class 5Full ranking →
Glaxo Group Limited 1,068 live
Novartis AG 964 live
Kenvue Inc. 674 live
Common questions

About Celgene Corporation trademarks.

How many trademarks does Celgene Corporation have?

183 live US trademarks as of October 23, 2026: 78 registered and 105 pending applications. 39 were filed in 2026 so far.

What does Celgene Corporation sell, according to its trademarks?

Mostly pharmaceuticals (Class 5, 149 live marks). Also medical & beauty services (Class 44) and science & technology (saas) (Class 42).

Who owns the THALOMID trademark?

THALOMID is owned by Celgene Corporation. It was registered on April 27, 1999 (Reg. No. 2242095) and is live. The same owner holds 182 other live US marks.

When did Celgene Corporation first file a trademark?

Its oldest live US filing dates from 1997: CELGENE, filed January 21, 1997.

Know the morning after Celgene Corporation files.

Watch this company in Thorgate and get an alert for every new application, registration, publication and lapse, with the opposition deadline already worked out. Or monitor your own marks for conflicts with theirs.

Watch this owner Monitor my marks

Data: USPTO trademark bulk files, processed nightly by Thorgate. Last rebuilt October 23, 2026. Counts cover the US federal register only, not state or foreign marks. Owner names are shown as recorded by the USPTO. This page reports public-record facts and dates and is not legal advice. For the official record of any mark, follow its serial number to USPTO TSDR.